- Home
- HLN vs ARGX Comparison
HLN vs ARGX Comparison
Compare HLN & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLN
- ARGX
- Stock Information
- Founded
- HLN 2022
- ARGX 2008
- Country
- HLN United Kingdom
- ARGX Netherlands
- Employees
- HLN N/A
- ARGX N/A
- Industry
- HLN Package Goods/Cosmetics
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLN Consumer Discretionary
- ARGX Health Care
- Exchange
- HLN Nasdaq
- ARGX Nasdaq
- Market Cap
- HLN 44.0B
- ARGX 37.3B
- IPO Year
- HLN N/A
- ARGX 2017
- Fundamental
- Price
- HLN $9.73
- ARGX $632.04
- Analyst Decision
- HLN Strong Buy
- ARGX Strong Buy
- Analyst Count
- HLN 2
- ARGX 20
- Target Price
- HLN $10.48
- ARGX $634.50
- AVG Volume (30 Days)
- HLN 6.8M
- ARGX 257.3K
- Earning Date
- HLN 08-01-2024
- ARGX 10-31-2024
- Dividend Yield
- HLN 1.61%
- ARGX N/A
- EPS Growth
- HLN N/A
- ARGX N/A
- EPS
- HLN 0.18
- ARGX N/A
- Revenue
- HLN $15,065,004,686.00
- ARGX $1,908,659,000.00
- Revenue This Year
- HLN $2.92
- ARGX $61.99
- Revenue Next Year
- HLN $2.80
- ARGX $42.48
- P/E Ratio
- HLN $26.81
- ARGX N/A
- Revenue Growth
- HLN N/A
- ARGX 85.56
- 52 Week Low
- HLN $7.89
- ARGX $349.86
- 52 Week High
- HLN $10.80
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- HLN 51.44
- ARGX 61.58
- Support Level
- HLN $9.60
- ARGX $617.88
- Resistance Level
- HLN $9.77
- ARGX $634.40
- Average True Range (ATR)
- HLN 0.12
- ARGX 13.71
- MACD
- HLN 0.01
- ARGX -0.28
- Stochastic Oscillator
- HLN 46.99
- ARGX 69.61
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.